Dendritic cell-based therapeutic vaccination for acute myeloid leukemia;Vaccination thérapeutique à base de cellules dendritiques contre la leucémie aiguë myéloïde

Bulletin du Cancer

Volumn 99, Issue 6, 2012, Pages 635-642

  Anguille, Sébastien ^a,b   Van Tendeloo, Vigor ^a,b   Berneman, Zwi ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acute myeloid leukemia; Dendritic cells; Immunotherapy; Therapeutic vaccination

Indexed keywords

DENDRITIC CELL VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; DISEASE CONTROL; HUMAN; IMMUNE SYSTEM; LEUKEMIA CELL; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; REVIEW;

EID: 84862873957     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1587     Document Type: Article

References (26)

1. Anguille S, Lion E, Smits E, Berneman ZN, Van Tendeloo VF. Dendritic cell vaccine therapy for acutemyeloid leukemia: Questions and answers. Hum Vaccines 2011; 7 : 579-84.
2. Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/ 1975-2007/results-single/sect-13-table.16.pdf. (Date de dernier accès : le 16 novembre 2011).
3. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368 : 1894-907. (Pubitemid 44794525)
4. Tuyaerts S, Aerts JL, Corthals J, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007; 56 : 1513-37. (Pubitemid 47094397)
5. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27 : 5195-201.
6. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89 : 1405-12. (Pubitemid 27080005)
7. Keilholz U, Menssen HD, Gaiger A, et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005; 19 : 1318-23. (Pubitemid 41136321)
8. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15 : 5323-37.
9. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acutemyeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107 : 13824-9.
10. van den Ancker W, van Luijn MM, Westers TM, et al. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy 2010; 2 : 69-83.
11. Li L, Giannopoulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 2006; 28 : 855-61.
12. Roddie H, Klammer M, Thomas C, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol 2006; 133 : 152-7.
13. Kremser A, Dressig J, Grabrucker C, et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother 2010; 33 : 185-99.
14. Curti A, Trabanelli S, Onofri C, et al. Indoleamine 2,3-dioxygenase- expressing leukemic dendritic cells impair a leukemiaspecific immune response by inducing potent T regulatory cells. Haematologica 2010; 95 : 2022-30.
15. Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, van Tendeloo VF. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 2009; 7 : 109.
16. Duncan C, Roddie H. Dendritic cell vaccines in acute leukaemia. Best Pract Res Clin Haematol 2008; 21 : 521-41.
17. Smits EL, Anguille S, Cools N, Berneman ZN, van Tendeloo VF. Dendritic cell-based cancer gene therapy. Hum Gene Ther 2009; 20 : 1106-18.
18. Khoury HJ, Collins RH, Blum W, et al. Prolonged administration of the telomerase vaccine GRNVAC1 is well tolerated and appears to be associated with favorable outcomes in high-risk acute myeloid leukemia (AML). Blood 2010; 116 : 2190.
19. Berneman ZN, Van de Velde A, Anguille S, et al. WT1-targeted dendritic cell vaccination as a post-remission treatment to prevent full relapse in acute myeloid leukemia. Blood 2010; 116 : 12-3.
20. Radford KJ, Turtle CJ, Kassianos AJ, et al. Immunoselection of functional CMRF-56+ blood dendritic cells from multiple myeloma patients for immunotherapy. J Immunother 2005; 28 : 322-31. (Pubitemid 40962325)
21. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10 : 475-80. (Pubitemid 38667904)
22. Fujii S, Shimizu K, Fujimoto K, et al. Treatment of posttransplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma 2001; 42 : 357-69. (Pubitemid 32725591)
23. Lee JJ, Kook H, Park MS, et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher 2004; 19 : 66-70. (Pubitemid 39006610)
24. Kitawaki T, Kadowaki N, Kondo T, et al. Potential of dendriticcell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpethemocyanin- pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am J Hematol 2008; 83 : 315-7. (Pubitemid 351458011)
25. Kitawaki T, Kadowaki N, Fukunaga K, et al. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Exp Hematol 2011; 39 : 424-33.
26. Kitawaki T, Kadowaki N, Fukunaga K, et al. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Br J Haematol 2011; 153 : 796-9.